Real-world data project will help FDA assess COVID-19 diagnostics

By staff writers

June 19, 2020 -- The U.S. Food and Drug Administration (FDA) plans to use real-world data to evaluate and foster development of COVID-19 molecular and antibody tests through a new multistakeholder public-private partnership.

The project -- called the Diagnostics Evidence Accelerator -- is being organized by the Reagan-Udall Foundation for the FDA with the Friends of Cancer Research. The Reagan Udall Foundation for the FDA is a nonprofit created by Congress with the mission of modernizing product development and accelerating innovation. Friends of Cancer Research is a nonprofit advocacy organization.

Among other things, the Diagnostics Evidence Accelerator will explore how to tailor testing strategies to specific patient populations and develop an in-depth understanding of antibodies and immunity. Assessing accuracy of diagnostics requires a different approach to data integration and analysis, Dr. Jeff Shuren, director of the FDA's Center for Devices and Radiological Health, explained in a statement.

"The aim of the Accelerator is to propose questions, refine them, evaluate the feasibility of different approaches, and bring together groups that have the data to answer the questions and develop lasting solutions," Shuren said. "Ultimately, we hope that real-world data can provide a more generalizable and rapid read-out of results than traditional clinical trials."

In addition to regulatory officials, the initiative will involve input from device manufacturers, professional societies, payers, and other stakeholders. It is a sister project to the Therapeutic Evidence Accelerator.

FDA issues warnings for misbranded COVID-19 antibody tests
The U.S. Food and Drug Administration (FDA) has issued warning letters to three companies for marketing "adulterated and misbranded" COVID-19 antibody...
FDA paves way for mass coronavirus screening of asymptomatic people
The U.S. Food and Drug Administration (FDA) has published guidance for diagnostics developers that it said will enable broad diagnostic testing of asymptomatic...
FDA finds false results with Chembio coronavirus antibody test, revokes clearance
The U.S. Food and Drug Administration (FDA) has revoked an emergency use authorization for Chembio Diagnostic Systems' antibody test for the novel coronavirus,...
New coronavirus lab test reporting rules address complaints on spotty data
By August 1, laboratories will need to comply with new demographic data reporting requirements for COVID-19 diagnostic tests, per guidance issued by the...
FDA airs antibody test performance specs, educational video
The U.S. Food and Drug Administration (FDA) has published detailed performance specifications for four more commercial antibody tests. Separately, the...

Copyright © 2020

Last Updated ls 6/19/2020 11:37:54 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current